HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

ClinicalTrials.gov ID: NCT01384734

Public ClinicalTrials.gov record NCT01384734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, efficacy, tolerability and pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1 infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.

Study identification

NCT ID: NCT01384734
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: ViiV Healthcare; Industry
Enrollment: 254 participants

Conditions and interventions

Conditions

Infection, Human Immunodeficiency Virus

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 26, 2011 (Actual)
Primary completion: Feb 18, 2013 (Actual)
Completion: May 12, 2017 (Actual)
Last update posted: Nov 14, 2018

2011 – 2017

United States locations

U.S. sites: 13
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
GSK Investigational Site	San Francisco	California	94102	—
GSK Investigational Site	San Francisco	California	94115	—
GSK Investigational Site	Washington D.C.	District of Columbia	20009	—
GSK Investigational Site	Coral Gables	Florida	33134	—
GSK Investigational Site	Orlando	Florida	32803	—
GSK Investigational Site	Atlanta	Georgia	30312	—
GSK Investigational Site	New York	New York	10008	—
GSK Investigational Site	Durham	North Carolina	27710	—
GSK Investigational Site	Cincinnati	Ohio	45267-0405	—
GSK Investigational Site	Philadelphia	Pennsylvania	19104	—
GSK Investigational Site	Austin	Texas	78705	—
GSK Investigational Site	Dallas	Texas	75246	—
GSK Investigational Site	Longview	Texas	75605	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01384734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 14, 2018 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01384734 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →